Answers are grounded in this paper and cite their sources.
Percutaneous closure of muscular ventricular septal defects has been well described and has not attracted the same controversy or scrutiny as perimembranous defect closure. Therefore, the development of specifically designed devices has been limited. We report the first use of the Occlutech® muscular ventricular septal defect device. Does its design add any significant benefit?
No takes yet. Share an insight, caveat, or question.
Gareth J. Morgan (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: